CLAIMS

1. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS 13 in the manufacture of a medicament for treatment of a blood clotting disorder in a mammal in need thereof by subcutaneous administration , wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram body weight.

2. The use of claim 1, wherein the blood clotting disorder is selected from the group consisting of inherited TTP, acquired TTP, cerebral infarction, myocardial infarction. ischemic/reperfusion injury, deep vein thrombosis, and sepsis-related disseminated intravascular coagulation.

3. The use of claim 1 or 2, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose.

4. The use of claim 1 or 2, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 50% as compared to intravenous administration normalized for the same dose.

5. The use of any one of claims 1-3, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 55% as compared to intravenous administration normalized for the same dose.

6. The use of any one of claims 1-3, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is at least 60% as compared to intravenous administration normalized for the same dose.

7. The use of any one of claims 1-3, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 65% as compared to intravenous administration normalized for the same dose.

8. The use of any one of claims 1-3, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is at least 70% as compared to intravenous administration normalized for the same dose.

9. The use of any one of claims 1-3, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 75% as compared to intravenous administration normalized for the same dose.

10. The use of claim 1 or 2, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 80% as compared to intravenous administration normalized for the same dose.

11. The use of any one of claims 1-10, wherein the blood clotting disorder is inherited TTP.

12. The use of claim 11, wherein the therapeutically effective amount comprises at least 20-160 activity units per kilogram body weight.

13. The use of any one of claims 1-10, wherein the blood clotting disorder is acquired TTP.

14. The use of claim 13, wherein the therapeutically effective amount comprises at least 40-2000 activity units per kilogram body weight.

15. The use of any one of claims 1-10, wherein the blood clotting disorder is cerebral infarction and/or ischemia reperfusion injury.

16. The use of claim 15, wherein the therapeutically effective amount comprises at least 40-4000 activity units per kilogram body weight.

17. The use of any one of claims 1-10, wherein the blood clotting disorder is myocardial infarction and/or ischemia reperfusion injury.

18. The use of claim 17, wherein the therapeutically effective amount comprises at least 40-2000 activity units per kilogram body weight.

19. The use of any one of claims 1-18, wherein the ADAMTS13 is to be administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.

20. The use of any one of claims 1-19, wherein the ADAMTS13 is recombinant.

21. The use of any one of claims 1-19, wherein the ADAMTS13 is plasma derived.

22. The use of any one of claims 1-21, wherein the mammal is a human.

23. The use of any one of claims 1-22, wherein the composition is a stable aqueous solution ready for administration.

24. The use of any one of claims 1-22, wherein the composition is lyophilized.

25. The use of claim 24, wherein the composition is reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.

26. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS 13 in the manufacture of a medicament for use in the treatment of a bleeding episode in a mammal in need thereof by, wherein the medicament is to be administered subcutaneously, and wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for a specific indication as measured in activity units per kilogram body weight.

27. The use of claim 26, wherein the specific indication is inherited TTP and the standard intravenous dose is 10-80 activity units per kilogram body weight.

28. The use of claim 26, wherein the specific indication is acquired TTP and the standard intravenous dose is 20-1000 activity units per kilogram body weight.

29. The use of claim 26, wherein the specific indication is myocardial infarction and/or ischemia reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram body weight.

30. The use of claim 26, wherein the specific indication is cerebral infarction and/or ischemia reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram body weight.

31. The use of any one of claims 26-30, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose.

31. The use of any one of claims 26-30, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose.

32. The use of any one of claims 26-30, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 50% as compared to intravenous administration normalized for the same dose.

33. The use of any one of claims 26-31, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 55% as compared to intravenous administration normalized for the same dose.

34. The use of any one of claims 26-31, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is at least 60% as compared to intravenous administration normalized for the same dose.

35. The use of any one of claims 26-31, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 65% as compared to intravenous administration normalized for the same dose.

36. The use of any one of claims 26-31, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is at least 70% as compared to intravenous administration normalized for the same dose.

37. The use of any one of claims 26-31, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 75% as compared to intravenous administration normalized for the same dose.

38. The use of any one of claims 26-30, wherein the bioavailability of the ADAMTS 13 after subcutaneous administration is at least 80% as compared to intravenous administration normalized for the same dose.

39. The use of any one of claims 26-38, wherein the ADAMTS 13 is to be administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.

40. The use of any one of claims 26-39, wherein the ADAMTS13 is recombinant.

41. The use of any one of claims 26-39, wherein the ADAMTS13 is plasma derived.

42. The use of any one of claims 26-41, wherein the mammal is a human.

43. The use of any one of claims 26-42, wherein the composition is a stable aqueous solution ready for administration.

44. The use of any one of claims 26-42, wherein the composition is lyophilized.

45. The use of claim 44, wherein the composition is reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.